September 2015: SMC decisions
The Scottish Medicines Consortium (SMC) has accepted the following medicines for NHS Scotland for particular indications: aflibercept (Eylea; Bayer); bortezomib (Velcade; Janssen-Cilag); ledipasvir/sofosbuvir (Harvoni; Gilead); lisdexamfetamine (Elvanse; Shire); pasireotide (Signifor; Novartis); sitagliptin (Januvia; Merck Sharp & Dohme). Bevacizumab (Avastin; Roche) has been accepted for restricted use in combination with pacitaxel only. Avanafil (Spedra; A Menarini) and elosulfase alfa (Vimizim; BioMarin) have not been accepted for use.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069323
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com